How the Clean The World Nonprofit Recycles Hotel Soap for Those in Need

Meet Shawn Siepler, the founder of Clean the World. The nonprofit recycles partially used soap left behind from hotel guests for those in need.When hotel or motel guests check into their rooms, they expect at the very least to be greeted with a clean space, a made-up bed and in the bathroom, soap.But what happens when you leave that soap behind?They typically end up in the trash, said Shawn Siepler, the founder of Clean the World, a nonprofit founded in 2009 that recycles bar soap from over 8,000 hospitality partners, including Marriott International and Walt Disney Resorts, for those in need. By collecting, melting, reforming and packaging partially used soap left behind by hotel guests, the nonprofit has distributed nearly 70 million bars of soap in more than 120 countries, including Romania, where many Ukrainian refugees have arrived.Clean the World currently focuses on repurposing bar soap in seven warehouses worldwide. Companies can enroll in the program online and receive boxes to collect discarded products at their properties. Full boxes are shipped to the nonprofit’s warehouses.The organization now has approximately 60 employees, but its beginning was far more humble, with Mr. Siepler and a small group of family and acquaintances scraping used soap by hand with potato peelers in a garage in Orlando.“The first time that the police came by the garage, they wanted to see what all of us Puerto Ricans were cooking. So I gave them a tour,” Mr. Siepler said during a video interview.The conversation has been edited for length and clarity.Before starting Clean the World, you traveled a lot as a sales executive. How did your job lead you to the nonprofit?I was traveling — New York on Monday, Chicago on Tuesday, St. Louis on Wednesday, Los Angeles, Thursday and back — and two clients that I personally managed were Target and Best Buy, both headquartered in Minneapolis. I was in Minneapolis in a hotel room when I came up with the concept of Clean the World.In Minneapolis, my alcohol consumption had to be increased to stay warm. So it was one of those nights that I’m like, “What happens to the soap?” and called the front desk to ask. And they said it was thrown away — they actually told me to have another cocktail.I was doing very well, but had an itch of wanting to do something on my own and thinking about sustainability and green technology as an entrepreneur. And that led to me ask, “What happens to the soap?” I was looking for items that could be recycled.The company started in your cousin’s single-car garage — tell me what those early days were like.I’m an original born-and-raised South Floridian, and we were collecting soap from hotels around the Orlando airport area in my cousin’s garage. We’d all sit around on upside-down pickle buckets with potato peelers, and we would scrape the outside of the bars of soap to surface clean it.My other cousin was on the meat grinder, and he would grind it down. And then we had these Kenmore cookers, and you would cook the soap. All the impurities would bubble up, and you’d wipe those off, and it would turn into this paste.Then we made big wood soap molds, and the paste would dry the next day. We’d wire-cut the bars, take them out and put them on racks.We had to have music on — salsa and merengue. Of course, we couldn’t get the power right when the meat grinder was on, so the power would cut out every 30 minutes.How did Clean the World become the operation it is today?We launched in the garage February 2009.We were distributing just to local charities in Orlando, and then we had an opportunity to go to Haiti in July of 2009. We take 2,000 bars of soap and go into a church that has 10,000 people in it. I remember just saying, “We’re gonna come back. We’re gonna bring more soap. I promise.”When we did that trip, our local Fox affiliate went with us and documented our work. When it ran in New York, it just so happened that Katie Couric was doing CBS Evening News and a senior producer called us in late August or September 2009 and said, “We want to do a piece on you.”Travel Trends That Will Define 2022Card 1 of 7Looking ahead.

Read more →

Why Are Sexually Transmitted Infections Surging?

After reaching historic lows more than a decade ago, rates are on the rise again.Last month, the Centers for Disease Control and Prevention released its latest data on cases of sexually transmitted infections during the first year of the pandemic. In the early months of 2020, the number of people diagnosed with gonorrhea and syphilis declined, as you might expect — it was, after all, a time of extreme isolation for many. Subsequently, though, infection rates surged so much that by the end of the year, the case counts were 10 percent and 7 percent higher than in 2019. In total, there were some 134,000 reports of syphilis and 678,000 reports of gonorrhea. These were “stunning” increases, says Hilary Reno, an associate professor at the Washington University School of Medicine and medical director of the St. Louis County Sexual Health Clinic. “I can’t tell you how many primary-care physicians have called me recently and said, ‘I just saw my first-ever case of syphilis this year.’”Indeed, syphilis was nearly eradicated in the United States around 2000; gonorrhea reached its lowest rates of infection in 2009. Many doctors who began practicing during that period haven’t had experience diagnosing these S.T.I.s, particularly in their female patients. According to Ina Park, a professor of family and community medicine at the University of California, San Francisco, “There’s an entire generation of physicians and clinicians who had never seen syphilis in women and babies before.”This is a significant problem: S.T.I.s can irrevocably damage the reproductive system. At least 20,000 women are rendered infertile by untreated S.T.I.s in the United States each year. Syphilis can cause sores and rashes and, if untreated for decades, fatal damage to the brain, heart and other organs. Gonorrhea can be painful and may result in pelvic inflammatory disease in women. Each condition is caused by bacteria and can be cured with antibiotics (though drug-resistant strains of the bacterium that causes gonorrhea are on the rise). Unfortunately, they are often asymptomatic, especially in women, and for them it can be harder to see signs of infection and easier to mistake some of those signs as normal discharge or yeast infections.The ease with which S.T.I.s spread undetected makes it crucial to screen for them regularly. Yet that is not happening. “The pandemic made S.T.I.s worse in America — for the first year, people all but stopped getting testing and treatment,” says David C. Harvey, executive director of the National Coalition of S.T.D. Directors, a trade association for state and local S.T.I. Health Department programs that collected its own data during the pandemic. (The C.D.C. data comes from a national surveillance system that includes mandatory lab reporting and sample surveys.) Moreover, contact tracers, assigned to notify sexual partners of exposure, were redeployed to focus on Covid.Historically, the highest rates of syphilis have been among gay and bisexual men, then among heterosexual men. And while that is still true, cases among gay and bisexual men have risen more slowly in recent years and even declined slightly in 2020. Cases among heterosexual women, on the other hand, increased 30 percent from 2018 to 2019 and 21 percent from 2019 to 2020, jumps that experts attribute in part to the increasing prevalence of opioid and methamphetamine abuse, which makes risky sexual behavior — transactional sex, condomless sex — more likely among all genders.Illustration by Ori ToorThis trend among women has fueled a corresponding surge in syphilis among newborns. In 2020, there was a nearly 15 percent increase in congenital syphilis — amounting to a 235 percent increase from 2016. Congenital syphilis can lead to severe lifelong health complications and stillbirth; of 2,148 infants who contracted syphilis in 2020, 149 did not survive. When women who are engaging in substance abuse become pregnant, they frequently avoid prenatal care for fear of being drug-tested and potentially losing custody of the child. That means many of them aren’t tested for syphilis and don’t receive the treatment that would prevent their baby from getting it. The C.D.C. recommends testing for the infection at the first prenatal visit and, for women who test positive or are at increased risk, early in the third trimester as well as at delivery. (Most states require doctors to perform the initial test, but only 19 also require screening in the third trimester.)Perhaps the simplest explanation for the overall rise in S.T.I.s between the 2000s and now is that lawmakers reallocated funding to other problems deemed more dire. Many S.T.I. clinics that provided free or low-cost testing and treatment closed or scaled back hours. Other factors contributed to the problem. The growth of online dating expanded sexual networks. The ability to prevent H.I.V. infection with prophylactic medication reduced the inhibitions against having sex without a condom. And most states still do not provide comprehensive sex education. If they did, more people would know that it’s important to treat S.T.I.s and not wait, says Whitney Irie, a lecturer in population medicine at Harvard Medical School. As it is, a popular impression is that S.T.I.s are “essentially obsolete,” she says. “I don’t think there’s a clear understanding, especially among people with a uterus, of the long-term impact on your reproductive organs. There’s this casualness about it that lends itself to being casual about preventive measures.”Reducing the burden of S.T.I.s will require outreach, particularly for marginalized groups, including women, people in the L.G.B.T.Q. community, Native Americans and Alaskan Natives and people of color, all of whom suffer disproportionately high rates largely because the health care system has neglected them. Black women, for example, have rates of syphilis, gonorrhea and chlamydia that are as much as seven times that of white women, and they face additional hurdles to receiving sexual health care. Black women, Irie says, must also contend with the “perceived stigma and perceived shame from their community” that receiving sexual health care means you don’t share its values, such as female monogamy. That’s a stereotype applied to women across many demographics.To reach those who have been disenfranchised, providers need to be trained to offer sexual health care to patients who have experienced historical trauma and sexual trauma, including assault and abuse. “If they’re met with a system that doesn’t use open terminology or doesn’t recognize their trauma, their experience can be horrible,” Reno says. “We can retraumatize them, and they don’t come back ever.”Public-health initiatives have also succeeded by partnering with local institutions people trust. In St. Louis, which has some of the nation’s highest rates of S.T.I.s, many barbershops and beauty salons offer testing information and free condoms; elsewhere, projects in partnership with churches have been able to increase mammograms and H.I.V. testing among Black women. Half of all new S.T.I. infections are among 15-to-24-year-olds, but school-based health centers that offer comprehensive health services on campus have been shown to improve attendance and graduation rates and decrease urgent-care visits.The pandemic has interrupted countless health services. But it also generated solutions. For example, in March 2020, a program called TakeMeHome began mailing out free H.I.V. self-test kits, with a focus on reaching gay and bisexual men. Half the recipients had not been tested within the previous year, and more than a third of them had never been tested at all; after using the kit, more than 10 percent reported accessing other sexual-health services. “You have to make it as easy for people as possible,” Park says.If you’re sexually active, you will inevitably be exposed to pathogens, just as you are by shaking hands with or breathing the same air as others. “Your clothes are off,” Park says. “That’s the only difference.” S.T.I.s “are not a personal failing,” Reno says. “This is a systemic societal challenge.” Thus, talking openly about sexual health care stands to benefit everyone. Park recommends pressing your provider for testing; ideally, S.T.I. screening would be treated like a trip to the dentist. “Put it in your routine as something you do regularly.”Kim Tingley is a contributing writer for the magazine.

Read more →

Targeting the Uneven Burden of Kidney Disease on Black Americans

New treatments aim for a gene variant causing the illness in people of sub-Saharan African descent. Some experts worry that focus will neglect other factors.In a Zoom call this spring with 19 leaders of A.M.E. Zion church congregations in North Carolina, Dr. Opeyemi Olabisi, a kidney specialist at Duke University, asked a personal question: How many of you know someone — a friend, a relative, a family member — who has had kidney disease?The anguished replies tumbled out from the assembled pastors:A childhood friend died, leaving a daughter behind.A father and sister felled by the disease.Uncles and sons lost.Three cousins and a brother-in-law on dialysis.None of this surprised Dr. Olabisi, who disclosed that he, too, had lost family members to the disease. His best friend, who had taught him to ride a bike in his native Nigeria, died of kidney failure in his early 30s.Kidney specialists have long known that Black Americans are disproportionately affected by kidney disease. While Black people make up about 12 percent of the U.S. population, they comprise 35 percent of Americans with kidney failure. Black patients tend to contract kidney disease at younger ages, and damage to their organs often progresses faster.Social disparities and systemic racism contribute to this burden, but there is also a genetic factor. Many with sub-Saharan ancestry have a copy of a variant of the gene APOL1 inherited from each parent, which puts them at high risk. Researchers have known for a decade that APOL1 is one of the most powerful genes underlying a common human disease.But there is hope now that much of this suffering can be alleviated. As many as 10 companies are working on drugs to target the APOL1 variants. And Dr. Olabisi has a federal grant to test whether baricitinib, a drug that treats rheumatoid arthritis, can help kidney patients with the variants.Yet the promise of treatments comes with difficult questions.Should genetic testing be offered and, if so, to whom? Although the variants increase risk, they do not preordain kidney disease. If someone knows that they have the variants, will they live in fear of kidney failure?There are as yet no proven ways to reduce the risk of kidney disease in those with two copies of the variants. Rigorous control of blood pressure — a major risk factor for progression of kidney disease — can be difficult to achieve in those who have the variants.“Now we know that the reason you can’t get your blood pressure down is because you have APOL1 kidney disease that is ferociously raising your blood pressure,” said Dr. Jeffrey Kopp, a kidney researcher at the National Institutes of Health. “It’s not your fault.”Despite their elation at the progress being made, some experts like Dr. Olabisi say that a laser focus on variants may let policymakers ignore the social and economic disparities underlying the disease.But, he added, “we don’t want to pretend that the biology doesn’t exist.” That, he said, “would not be doing the community any good.”Dr. Opeyemi Olabisi in the Duke Molecular Physiology Institute in Durham, N.C. He has lost friends and family members to kidney disease.Cornell Watson for The New York TimesA Farmer Provides a ClueWhile it has long been known that kidney failure occurs in African Americans five times as much in as it does in white Americans, “We had never been able to understand all the reasons,” said Dr. Neil Powe, a professor of medicine and an epidemiologist at the University of California, San Francisco.Researchers began looking for a genetic cause. Finally, a little more than a decade ago, a Havard team led by Giulio Genovese, Dr. David Friedman and Dr. Martin Pollak found it: variants of APOL1 that ramped up the gene’s activity.Understand Sickle Cell DiseaseThe rare blood disorder, which can cause debilitating pain, strokes and organ failure, affects 100,000 Americans and millions of people globally, mostly in Africa.The Global Epicenter: In Nigeria, where 150,000 babies are born each year with sickle cell disease, the effects of the condition are pervasive and devastating. On the Edge of Fear: A cure for the disease, which in the United States mostly affects Black people, seems near. For some, it may come too late.Preventing Complications: A legacy of neglect toward Americans with sickle cell means that patients may not receive the treatments needed to stave off the disease’s risks. A Haunting Memory: The Times reporter Gina Kolata shares her experience reporting on the inequities in access to medical advances in the treatment of the disease.It was a complete surprise. APOL1 is part of the immune system and can destroy trypanosomes — protozoa that can cause illnesses. But no one expected it to have anything to do with the kidneys.It turns out that the variants rose to a high frequency among people in sub-Saharan Africa because they offer powerful protection against deadly African sleeping sickness, a disease caused by trypanosomes. It is reminiscent of another gene variant that protects against malaria but causes sickle cell disease in those who inherit two copies. That variant became prominent in parts of Africa and other areas of the world where malaria is common, but sickle cell variants are much less common than APOL1 risk variants.About 39 percent of Black Americans have one copy of the gene’s risk variants; another 13 percent, or nearly 5.5 million, have two copies. Those with two copies are at increased risk for fast progressing kidney disease that often starts in young adulthood. Approximately 15 percent to 20 percent of those with two copies develop kidney disease in their lifetime.In contrast, 7.7 percent of Americans with African ancestry have one copy of the sickle cell variant, and 0.3 percent have two copies.“What nature gave with one hand, it took away with the other,” Dr. Olabisi said.One way to treat kidney disease might be using medicines that block the gene and its variants from acting in the body. But researchers had to find out if APOL1 was necessary for kidney function. If it was, drugs that blocked it might do more harm than good.Researchers found an answer: A farmer in India had no APOL1 gene. His kidneys were totally healthy.Often, in drug development, Dr. Friedman says, the drug dose has to be fine tuned — too much is dangerous and too little is useless. The discovery of the farmer, he said, “tells you you can probably drive the level of the APOL1 protein very low.”But ethical issues have tempered some experts’ enthusiasm about the genetic discoveries.Harriet A. Washington, a lecturer in ethics at Columbia University and author of the book “Medical Apartheid,” worries that knowledge of the role of APOL1 variants can drive the medical establishment toward “a blame-the-victim approach signaling an inherent flaw in African Americans.”The implication, she said: “This is something happening in nature, so what can we do about it?” Such an attitude, she added, “invites futility and absolves health care from treating sufferers.”Joseph L. Graves, Jr., a professor of biological sciences at North Carolina Agricultural and Technical State University, raised another issue. “We don’t want to fall into the myth of the genetically sick African,” he said.“All populations have genetic variants, but the action of those variants is determined by the environment in which those people live,” Dr. Graves explained. “People want to find simple explanations for complex phenomena. Find a genetic variant and make the story simple, but that’s not how it works. Environmental effects are really important.”He added that for Black Americans, profound environmental effects rise from structural racism — inequitable effects of law and policies — which can lead to a lack of access to health care, including preventive care to ward off chronic illness.Erika Blacksher, an ethicist at the nonprofit Center for Practical Bioethics in Kansas City, Mo., added that while finding “a treatment that might counteract the effect of the genetic variant is good news,” she worried that social inequities could not be disentangled from the high rate of kidney disease among those with sub-Saharan African ancestry, not all of whom have the APOL1 variant. Emphasizing the variants, she said, “deflects from our social responsibility to actually change the conditions that contribute to the onset of chronic kidney disease.”Making a PlanMalcolm, left, and Martin Lewis, 26, have lupus, an autoimmune disease that attacks the body’s tissues and organs.Amir Hamja for The New York TimesMartin and Malcolm Lewis, 26-year-old identical twins, have lupus, an autoimmune disease that can ravage the body’s organs. So when Martin developed kidney disease at age 10, his doctors said lupus was to blame.In July 2020, Martin, an actor who lives in Brooklyn, was visiting Malcolm, a data analyst who was hospitalized at Duke with a lupus flare-up. There, the brothers met Dr. Olabisi, who told them about APOL1.They discussed his research project, which involves testing Black Americans and enrolling those with the variant and with kidney disease in a study of the arthritis drug. He invited them to participate and asked if they wanted to know if they had APOL1 variants.“I was all for it,” Malcolm said. So was Martin.When they were tested, the brothers learned they had the variants and that the variants, not lupus, most likely were damaging their kidneys. They hardly knew how to react.“I am still trying to grapple with it,” Malcolm said.But Dr. Olabisi was not surprised. Researchers think the variants cause kidney disease only when there is a secondary factor. A leading candidate is the body’s own antiviral response, interferon, which is produced in abundance in people with lupus.High levels of interferon also occur in people with untreated H.I.V. As happens in people with Covid-19, they can suffer an unusual and catastrophic collapse of their kidneys if they have the variants. Other viral infections, including some that may go unnoticed, can elicit surges of interferon that could set off the APOL1 variants. Interferon is also used as a drug to treat some diseases including cancer and was tested as a treatment for Covid patients.For now, there is little Malcolm and Martin can do except take medications to control their lupus.Martin said he understands all that, but he’s glad he learned he has the variants. Now, he knows what he might be facing.“I’m the kind of person who likes to plan,” he said. “It does make a difference.”From a Gene to DrugsWhile Dr. Olabisi is waiting to start his study, a drug company, Vertex, has forged ahead with its own research. But there was no agreement on how APOL1 variants caused kidney disease, so it was not clear what a drug was supposed to block.“If you don’t understand the mechanism, that means you can’t measure effects in a lab,” said Dr. David Altshuler, chief scientific officer at Vertex. “And if you can’t measure effects in the lab, that means you can’t correct them.”It was known how the APOL1 protein protected against sleeping sickness — it punched holes in the disease-causing trypanosomes, making them swell with fluid and burst.Vertex researchers hypothesized that the variants spurred APOL1 proteins to punch holes not just in trypanosomes but also in kidney cells.What followed was years of work in lab studies and in animals given genes for human APOL1 variants and then screening about a million compounds that might block APOL1.Finally, the researchers settled on a drug that worked in animal models.Vertex tested the experimental drug in a 13-week study in patients with advanced kidney disease. The drug reduced the amount of protein in their urine by 47.6 percent, a sign of improved kidney function.In late March, the company announced it would take the next step — a clinical trial that would enroll approximately 66 patients in the first phase, to find the best dose, and 400 in the next phase, to see if the drug could improve kidney functions in patients with the risk variants and kidney damage and protect them from developing kidney failure or dying.Other companies began later and have revealed less about their plans and progress. AstraZeneca, for example, would only say that it was in the early stages of testing a drug that could bind to APOL1 mRNA, the messenger that carries instructions from the gene to cells’ protein making machinery.MAZE, a small biotech company, is pursuing a strategy similar to the Vertex one, said Dr. Sekar Kathiresan, a co-founder and board member.“I’m optimistic this can move quickly,” Dr. Kathiresan said.Using Their PulpitsAt the meeting with the pastors in North Carolina, Dr. Olabisi said he hoped to test 5,000 Black members of the community for kidney disease with a simple urine test and to use a saliva test to detect APOL1 variants. Testing of the arthritis drug would follow.“I’m in,” said the Rev. Dr. Daran Mitchell, the pastor of Trinity A.M.E. Zion Church in Greensboro, N.C.He and the other pastors were enthusiastic. It would be a community effort, led by people in the community and promoted on social media. Subjects could be tested in churches or in community centers or in their homes. And it was a way to advance the day when a treatment would be available.Dr. Olabisi smiled.“This gives me energy and a lot of hope,” he said.

Read more →

What a Gene and Its Risks Could Mean for Kidney Transplants

Kidneys from Black donors are automatically downgraded in transplant assessments, but studying a gene variant could help change that.Transplant specialists, when evaluating kidneys that come from donors, try to work out how likely it is that the kidney will fail after being transplanted into a recipient. Their risk calculations consider factors including the donor’s age, height, weight and history of diabetes. And, to the dismay of some researchers, it also includes the donor’s race.Kidneys from Black donors, living or dead, are automatically downgraded as higher risk.Some experts are now asking if there is a better way of evaluating kidneys from Black donors, one that can rely more on genetic screening rather than race to assess the risk of failure.The proposed genetic screening would check whether donors carry two copies of variants in a gene, APOL1, that are strongly associated with kidney disease. Because most Black donors do not have those genetic variants, the experts argue, their kidneys should not be automatically downgraded.But before instituting that change, researchers say they have to determine if, in fact, kidneys from donors that have the risk variants of APOL1 are more likely to fail.The first hint came from a study by Dr. Barry Freedman, of Wake Forest University in North Carolina involving 1,153 deceased donor kidney transplants performed at 113 different transplant programs. It found that kidneys from deceased donors with two risk variants were twice as likely to fail rapidly compared with kidneys from donors who have one gene variant or none.But that finding will need to be replicated in a bigger research effort. It is getting underway with APOLLO, a large study sponsored by the National Institutes of Health, to assess living and deceased donors. Study researchers are testing kidney donors for APOL1 and following the fate of thousands of transplant patients who have received kidneys from Black American donors at more than 97 transplant programs.In the study, living donors can decide if they want to learn the result of their genetic test and if they want the recipient of their kidney to know the result as well. Medical privacy regulations forbid doctors from telling kidney transplant candidates if a living donor has the variants without the donor’s consent.Dr. Freedman said that whatever results come from the research, more transplant centers are broaching the idea of genetic testing people who want to donate kidneys.Until recently, he added, “many transplant centers said they don’t want to talk about it.”

Read more →

India’s construction workers bear the brunt of heatwave

Thousands of Indians are reeling under a brutal heatwave that has swept through the country.Some areas of the capital, Delhi, have recorded temperatures of 49C.But life has become hardest for the working poor – vast swathes of people employed in the country’s unorganised sector – who are struggling to cope with the soaring temperatures. With no other means of livelihood, they toil through the day in soaring temperatures to ensure they and their families don’t go hungry.Video edited by Anshul Verma

Read more →

New method melds data to make a 3-D map of cells' activities

Just as it’s hard to understand a conversation without knowing its context, it can be difficult for biologists to grasp the significance of gene expression without knowing a cell’s environment. To solve that problem, researchers at Princeton Engineering have developed a method to elucidate a cell’s surroundings so that biologists can make more meaning of gene expression information.
The researchers, led by Professor of Computer Science Ben Raphael, hope the new system will open the door to identifying rare cell types and choosing cancer treatment options with new precision. Raphael is the senior author of a paper describing the method published May 16 in Nature Methods.
The basic technique of linking gene expression with a cell’s environment, called spatial transcriptomics (ST), has been around for several years. Scientists break down tissue samples onto a microscale grid and link each spot on the grid with information about gene expression. The problem is that current computational tools can only analyze spatial patterns of gene expression in two dimensions. Experiments that use multiple slices from a single tissue sample — such as a region of a brain, heart or tumor — are difficult to synthesize into a complete picture of the cell types in the tissue.
The Princeton researchers’ method, called PASTE (for Probabilistic Alignment of ST Experiments), integrates information from multiple slices taken from the same tissue sample, providing a three-dimensional view of gene expression within a tumor or a developing organ. When sequence coverage in an experiment is limited due to technical or cost issues, PASTE can also merge information from multiple tissue slices into a single two-dimensional consensus slice with richer gene expression information.
“Our method was motivated by the observation that oftentimes biologists will perform multiple experiments from the same tissue,” said Raphael. “Now, these replicate experiments are not exactly the same cells, but they’re from the same tissue and therefore should be highly similar.”
The team’s technique can align multiple slices from a single tissue sample, categorizing cells based on their gene expression profiles while preserving the physical location of the cells within the tissue.

Read more →

Scientists identify characteristics to better define long COVID

A research team supported by the National Institutes of Health has identified characteristics of people with long COVID and those likely to have it. Scientists, using machine learning techniques, analyzed an unprecedented collection of electronic health records (EHRs) available for COVID-19 research to better identify who has long COVID. Exploring de-identified EHR data in the National COVID Cohort Collaborative (N3C), a national, centralized public database led by NIH’s National Center for Advancing Translational Sciences (NCATS), the team used the data to find more than 100,000 likely long COVID cases as of October 2021 (as of May 2022, the count is more than 200,000). The findings appeared May 16 in The Lancet Digital Health.
Long COVID is marked by wide-ranging symptoms, including shortness of breath, fatigue, fever, headaches, “brain fog” and other neurological problems. Such symptoms can last for many months or longer after an initial COVID-19 diagnosis. One reason long COVID is difficult to identify is that many of its symptoms are similar to those of other diseases and conditions. A better characterization of long COVID could lead to improved diagnoses and new therapeutic approaches.
“It made sense to take advantage of modern data analysis tools and a unique big data resource like N3C, where many features of long COVID can be represented,” said co-author Emily Pfaff, Ph.D., a clinical informaticist at the University of North Carolina at Chapel Hill.
The N3C data enclave currently includes information representing more than 13 million people nationwide, including nearly 5 million COVID-19-positive cases. The resource enables rapid research on emerging questions about COVID-19 vaccines, therapies, risk factors and health outcomes.
The new research is part of a related, larger trans-NIH initiative, Researching COVID to Enhance Recovery (RECOVER), which aims to improve the understanding of the long-term effects of COVID-19, called post-acute sequelae of SARS-CoV-2 infection (PASC). RECOVER will accurately identify people with PASC and develop approaches for its prevention and treatment. The program also will answer critical research questions about the long-term effects of COVID through clinical trials, longitudinal observational studies, and more.
In the Lancet study, Pfaff, Melissa Haendel, Ph.D., at the University of Colorado Anschutz Medical Campus, and their colleagues examined patient demographics, health care use, diagnoses and medications in the health records of 97,995 adult COVID-19 patients in the N3C. They used this information, along with data on nearly 600 long COVID patients from three long COVID clinics, to create three machine learning models to identify long COVID patients.
In machine learning, scientists “train” computational methods to rapidly sift through large amounts of data to reveal new insights — in this case, about long COVID. The models looked for patterns in the data that could help researchers both understand patient characteristics and better identify individuals with the condition.
The models focused on identifying potential long COVID patients among three groups in the N3C database: All COVID-19 patients, patients hospitalized with COVID-19, and patients who had COVID-19 but were not hospitalized. The models proved to be accurate, as people identified as at risk for long COVID were similar to patients seen at long COVID clinics. The machine learning systems classified approximately 100,000 patients in the N3C database whose profiles were close matches to those with long COVID.
“Once you’re able to determine who has long COVID in a large database of people, you can begin to ask questions about those people,” said Josh Fessel, M.D., Ph.D., senior clinical advisor at NCATS and a scientific program lead in RECOVER. “Was there something different about those people before they developed long COVID? Did they have certain risk factors? Was there something about how they were treated during acute COVID that might have increased or decreased their risk for long COVID?”
The models searched for common features, including new medications, doctor visits and new symptoms, in patients with a positive COVID diagnosis who were at least 90 days out from their acute infection. The models identified patients as having long COVID if they went to a long COVID clinic or demonstrated long COVID symptoms and likely had the condition but hadn’t been diagnosed.
“We want to incorporate the new patterns we’re seeing with the diagnosis code for COVID and include it in our models to try to improve their performance,” said the University of Colorado’s Haendel. “The models can learn from a greater variety of patients and become more accurate. We hope we can use our long COVID patient classifier for clinical trial recruitment.”
This study was funded by NCATS, which contributed to the design, maintenance and security of the N3C Enclave, and the NIH RECOVER Initiative, supported by NIH OT2HL161847. RECOVER is coordinating, among others, the participant recruitment protocol to which this work contributes. The analyses were conducted with data and tools accessed through the NCATS N3C Data Enclave and supported by NCATS U24TR002306.

Read more →

Vaccinia virus pulls together a makeshift tool to repair its DNA, exposing a vulnerability that could be targeted

Instead of relying on the cell’s repair mechanisms, the vaccinia virus MacGyvers a tool for DNA repair from one that it already uses to copy DNA, reports a team of researchers at the Medical University of South Carolina (MUSC) in the Journal of Virology. Blocking that tool — an enzyme known as polymerase — at once disrupts the virus’s ability to copy and to repair DNA, exposing an Achilles’ heel that could be targeted with a therapeutic.
“For vaccinia virus, polymerase is a Sawzall — a tool that you can use for everything” said Paula Traktman, Ph.D., senior author of the article and dean of the College of Graduate Studies at MUSC, who has studied the virus for decades. “Viruses have smaller chromosomes, and so they’ve evolved to be able to use their tools for different things.”
“It’s like the virus’s Swiss Army knife,” said Conor Templeton, Ph.D. lead author of the article, who was a predoctoral candidate in the Traktman laboratory during the study and has since completed his doctorate. “It’s a protein that’s involved in replicating or copying DNA, but it also seems to be involved in repair.”
Such detailed basic science findings about the way viruses copy and repair their DNA have paved the way for breakthrough antiviral therapies in the past 20 years, said Traktman.
“HIV antiretroviral drugs were made by really painstaking analysis of which proteins in the virus are essential, leading to drugs that now have made it a chronic disease,” she said. “A curative treatment for hepatitis C was made possible by painstaking analysis of which proteins are essential for the virus. The more we know about the enemies, the better the weapons we can develop against them.”
Better therapies for pox viruses are certainly needed. The vaccinia virus is a close relative of the virus causing smallpox and was used in the vaccine that successfully eradicated it in the late 20th century. Although smallpox no longer naturally occurs, the threat that it might be used as a bioweapon remains, and currently, there is only one approved antiviral agent against it. Other pox viruses, most notably monkeypox, continue to afflict humans and can be lethal.

Read more →

Ultra-powerful brain scanners offer hope for treating cognitive symptoms in Parkinson's disease

Ultra-powerful 7T MRI scanners could be used to help identify those patients with Parkinson’s disease and similar conditions most likely to benefit from new treatments for previously-untreatable symptoms, say scientists.
Both Parkinson’s disease and a related disorder, progressive supranuclear palsy (PSP), are progressive brain diseases that not only affect movement but also damage motivation and cognition. These latter symptoms can have a major impact on a patient’s outcome, affecting their survival and general wellbeing, as well as the stress and costs for families.
To understand the causes of these cognitive symptoms, researchers at the University of Cambridge used a new ultra-high strength ‘7T’ MRI scanner at the Wolfson Brain Imaging Centre to measure changes in the brains of people with Parkinson’s disease, PSP, or in good health. 7T refers to the strength of the magnetic field; most MRI scanners tend to be 3T or below.
The results are published today in the journal Movement Disorders.
Patients with Parkinson’s disease and PSP are often treated with drugs such as L-DOPA, which compensate for the severe loss of dopamine. But, dopamine treatment does little for many of the non-motor symptoms. That is why scientists have begun to turn their attention to noradrenaline, a chemical that plays a critical role in brain functions including attention and arousal, thinking and motivation.
Professor James Rowe from the Department of Clinical Neurosciences at the University of Cambridge, who led the study, said: “Noradrenaline is very important for brain function. All of our brain’s supply comes from a tiny region at the back of the brain called the locus coeruleus — which means ‘the blue spot’. It’s a bit like two short sticks of spaghetti half an inch long: it’s thin, it’s small, and it’s tucked away at the very base of the brain in the brain stem.”
A study last year from Professor Rowe’s team, examining brains donated to the Cambridge Brain Bank, found that some people with PSP had lost as much as 90% of the noradrenaline-producing locus coeruleus.

Read more →

Anti-abortion groups target women with misleading ads

SharecloseShare pageCopy linkAbout sharingImage source, Getty Images When Hana found out she was pregnant, she searched Google for “abortion clinics near me”. The first result – a neutral-looking website offering a free consultation – looked like her best bet. It wasn’t until the 19-year-old was walking down corridors of the north-eastern US clinic, lined with posters comparing the procedure to murder, that she realised this was not an abortion provider – its purpose was to talk her out of her decision.In many US states, BBC News has seen misleading websites advertising these clinics appearing high up in Google search results – and Facebook adverts with inaccurate medical advice – while genuine abortion providers are having their ads rejected and accounts restricted. Advice centres, such as the one visited by Hana, are often run by Christian organisations.They may offer some medical services such as pregnancy tests and ultrasounds – but some of their online promotion falsely suggests they also provide pregnancy-termination services.’Get care’Hana describes herself as a “nerdy researcher”, studying a health-related course at college – but nothing about the clinic’s website tipped her off to the service it actually provides. The home page says: “Take control – start with a free abortion consultation.” And in a tab labelled: “Get care,” it lists the types of abortion (medical and surgical) that can be performed during different trimesters of pregnancy, under the heading: “You just found out you’re pregnant and want to know your options.”Once there, Hana says, she was told, inaccurately, abortions were linked to infertility and breast cancer – and having had a Covid-19 vaccine, she might lose the pregnancy anyway, making abortion unnecessary, despite the evidence suggesting vaccinated people are no more likely to miscarry and, in fact, better protected against the risks of pre-term and still birth associated with Covid.She was also pressured to view the ultrasound scan against her wishes. “What kind of mother doesn’t want to see a picture of their child?” asked the person attending to her.Hana was left feeling deceived and betrayed. ‘Choose life’The Human Coalition, an anti-abortion group providing marketing for the centre and more than 40 others, told BBC News: “We find in our work, most abortion-determined women do not desire an abortion, they desire help.”We’re here to empower women by filling that gap – connecting women to the care and support they want, to choose life.”Image source, Contributor’s own photoGoogle displays adverts above search results for certain terms. Advertisers bid to have their ads appear first, Google says, although the order should also be determined by “relevance” and “overall quality”. But, Whitney Chinogwenya, of MSI Reproductive Choices (formerly Marie Stopes international) says, this creates a “battle of budgets”, with regulated abortion clinics competing with anti-abortion clinics or unregulated pill providers for ad space on specific search terms. Several large global abortion providers have also told BBC News they regularly have their online material referring to abortion censored without explanation, including having YouTube channels suspended, social-media accounts restricted and Facebook and Google ads rejected. In 2019, having been criticised for hosting misleading adverts, Google tried to crack down on abortion-advice clinics, which are most common in the US but can also be found across Europe (including the UK), Africa and Latin America. In the US, UK and Ireland, anyone running an ad mentioning abortion must first apply for a certificate. Ads from advice clinics not offering abortions can still run but will be given a disclaimer the advertiser “does not provide abortions”.Image source, Hana/GoogleHana says she did not see this disclaimer.It appears in very small font underneath the search headline and description. Sarah Eagan, a researcher for campaign group the Center for Countering Digital Hate, questions whether Google should be taking money at all for anti-abortion ads that target keywords used by people actively seeking terminations.The CCDH has also found anti-abortion ads promoting unproven medicines remaining on Facebook.And at the other end of the spectrum, the researchers found Google’s autocomplete function suggesting ineffective do-it-yourself abortion methods.Kelly, like Hana, says she was given inaccurate medical information as she struggled to find an affordable and safe way to terminate her pregnancy in her home state of Texas. What is Roe v Wade ruling on abortion? What happens if Roe v Wade is overturnedImage source, Getty ImagesBetween jobs and without insurance, she could not afford “an actual doctor’s visit” so searched for affordable clinics. Finding her way to an anti-abortion centre, Kelly says she was frightened with warnings she could “bleed out” and risk her life but not given the context medical abortion is an extremely safe procedure.Kelly feels promoting free pregnancy tests targets low-income women.The centre appears to be using organic search, not adverts, making it more complicated to regulate. It says its website clearly states: “We do not refer or perform abortions,” adding it provides “free services annually to over 5,000 minority poor under-served single mothers”. Image source, Getty ImagesEventually, Kelly was prescribed termination drugs – just hours before she passed the 12-week limit for a safe medical abortion. But Elisa Wells, co-founder of Plan C, the organisation that helped Kelly access these abortion pills, says its online material is routinely “disallowed for violating community standards” on Facebook, Instagram and Google. Google says it has clear policies governing abortion-related ads, some determined by local laws and regulations.Some of the posts and channels flagged by BBC News had been removed in error and since reinstated, it said.Facebook said it had restored a small number of incorrectly rejected ads for abortion providers.Read more from Reality CheckSend us your questions

Read more →